Countable Labs targets CGT QC gaps

Cell and gene therapy labs live or die on measurement. Not the flashy biology part — the unglamorous part where a team has to prove what is in a vector, how much of it is there, and whether the same answer holds from R&D through QC. That is the gap Countable Labs is trying to hit. The company is pushing its Countable PCR platform as a way to close some of the nastiest quality-control holes in CGT workflows, especially where current PCR methods get noisy, waste sample, or force labs to bounce between assays. ### What is the actual problem here? CGT analytics are messy because the same program needs different kinds of answers at different stages. Early teams want fast development data. Later teams need methods that transfer cleanly into QC and support filings and batch release. But the standard toolkit often fragments that work — qPCR for one job, droplet digital PCR for another, sometimes NGS for deeper characterization. Countable’s pitch is that this handoff is where time, reproducibility, and confidence get lost. (countablelabs.com) ### Why are current methods such a pain? The short version is tradeoffs. qPCR is fast, but less absolute. dPCR improves precision, but can bring dead volume loss, statistical ambiguity, and more workflow complexity. NGS can answer harder questions, but usually with more overhead than a QC team wants for routine release work. In CGT, that means labs can end up running separate assays for vector titer, genome integrity, residual DNA, and impurities — basically stitching together a picture from multiple tools. (countablelabs.com) ### So what is Countable Labs saying it built? Countable says its platform directly counts single molecules after isolating them in more than 30 million compartments in a 3D gel matrix. The company’s headline claim is 10x more sensitivity and 10x lower coefficient of variation than digital PCR. That is the core technical promise — fewer borderline calls, better rare-event detection, and more confidence when sample is scarce. In CGT, scarce sample is not some edge case. (countablelabs.com) It is normal. ### Why does single-molecule counting matter for QC? Because QC hates inference. A lot of legacy workflows estimate from thresholds, partitions, or stitched-together assays. Countable is arguing that direct counting reduces that fuzziness and makes methods easier to transfer across teams. The company also says the same platform can support copy number, residual DNA, titer, and genome integrity work — which is a big deal if true, because every extra platform in a regulated workflow adds validation burden and handoff risk. (businesswire.com) ### Where does this show up in a real CGT workflow? Mostly in vector characterization and release-adjacent testing. Countable’s CGT materials focus on measuring genomic titer reproducibly, checking partial versus complete genomes, and combining integrity, impurity, and titer readouts in one multiplexed reaction. Think of it like replacing a bench full of specialized rulers with one ruler that can measure several dimensions at once — not perfectly universal, but much simpler for the people who have to run the test every day. (countablelabs.com) ### Is this just a concept, or is the company actually commercial now? It is commercial. Countable launched Countable PCR in May 2025, added a 10-color platform in October 2025, and said in March 2026 that its Countable 4 platform received CE marking for Europe. The company is also leaning into compliance language around 21 CFR Part 11 software features, which tells you it wants to be taken seriously by regulated labs, not just research groups. (countablelabs.com) ### What is the catch? The catch is that every platform vendor says it can consolidate workflows. The real test is method adoption inside conservative CGT organizations — then reproducibility across sites, operators, and regulated handoffs. Countable clearly understands the pain point. But turning a better measurement idea into a standard QC method is slower than launching an instrument. (businesswire.com) ### Bottom line? This story is not really about another PCR machine. It is about whether CGT labs can stop treating analytics as a patchwork exercise. Countable Labs is betting that direct single-molecule counting can turn QC from a bottleneck into a shared language across development, tech transfer, and release. If that works, the value is not just better data — it is fewer delays between making a therapy and proving it is ready. (countablelabs.com)